Loading…
Zevra Therapeutics Inc
Zevra Therapeutics Inc (ZVRA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Boston, United States and has 61 employees. The company is worth $590.27M and trades at 10.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $106.47M in fiscal 2025, up 350.9% from the year before. Net income was $83.23M. The share price is 33.9% below its 52-week high of $15.04. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $2.74M. In that quarter, 1 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $224.95K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +26.9% over 5Y.
today you would have $1,046.32▲ +4.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.96 | $8.34 | $6.55 | $4.59 | $8.71 | $11.20 | $6.06 | $28.48 | $64.80 | $47.20 | $317.76 | |
| P/E | — | 6.6x | — | — | — | — | — | — | — | — | — | — |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IRWDIronwood Pharmaceuticals Inc | $3.57 | 4.6x | — | 0.00% | — | $589.91M |
| AVRAnteris Technologies Global Corp. | $6.05 | — | 2.3x | 0.00% | -74.65% | $589.62M |
| WEAVWeave Communications, Inc. | $7.39 | — | 7.0x | 0.00% | -25.08% | $594.53M |
| PBYIPuma Biotechnology Inc |
| P/S |
| 10.5x |
| 4.9x |
| 19.1x |
| 10.4x |
| 15.6x |
| 10.5x |
| 23.9x |
| 1.5x |
| — |
| — |
| — |
| — |
| P/B | 3.4x | 3.4x | 11.4x | 4.6x | 2.1x | 2.9x | — | — | — | — | — | — |
| EPS | $1.35 | -$2.28 | -$1.30 | -$0.78 | -$2.11 | -$3.21 | -$13.23 | -$50.40 | -$47.36 | -$18.08 | -$118.72 |
| Profit margin | -167.69% | 78.17% | -446.85% | -167.69% | -263.48% | -29.86% | -96.03% | -191.00% | — | — | — | — |
| ROE | -35.64% | 53.82% | -266.00% | -74.44% | -35.64% | -8.42% | — | — | — | — | — | — |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
2 methods answered, across 1 families.
Room for errors in the reported numbers.
+56.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $11.26 |
| 21.2x |
| 4.2x |
| 0.00% |
| 21.97% |
| $581.24M |
| AVTXAvalo Therapeutics, Inc. | $11.27 | — | 1.3x | 0.00% | -36.27% | $604.41M |
| NVCTNuvectis Pharma, Inc. | $18.60 | — | 54.7x | 0.00% | -214.58% | $607.18M |